Connolly, KR; Thase, ME (2016). «Vortioxetine: a New Treatment for Major Depressive Disorder.». Expert Opinion on Pharmacotherapy17 (3): 421–31. doi:10.1517/14656566.2016.1133588. PMID26679430. «The authors suggest that vortioxetine is currently a good second-line antidepressant option and shows promise, pending additional long-term data, to become a first-line antidepressant option.».
Köhler, Stephan; Cierpinsky, Katharina; Kronenberg, Golo; Adli, Mazda (2016). «The serotonergic system in the neurobiology of depression: Relevance for novel antidepressants». Journal of Psychopharmacology30 (1): 13–22. doi:10.1177/0269881115609072. PMID26464458.
«Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder». Journal of Medicinal Chemistry54 (9): 3206–21. May 2011. doi:10.1021/jm101459g. PMID21486038.
N. Moore; B. Bang-Andersen; L. Brennum; K. Fredriksen; S. Hogg; A. Mork; T. Stensbol; H. Zhong και άλλοι. (August 2008). «Lu AA21004: a novel potential treatment for mood disorders». European Neuropsychopharmacology18 (Supplement 4): S321. doi:10.1016/S0924-977X(08)70440-1.
Sanchez, C; Asin, KE; Artigas, F (1 January 2015). «Vortioxetine, a Novel Antidepressant with Multimodal Activity: Review of Preclinical and Clinical Data». Pharmacology & Therapeutics145: 43–57. doi:10.1016/j.pharmthera.2014.07.001. ISSN1879-016X. PMID25016186.
Sanchez, C; Asin, KE; Artigas, F (2015). «Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data». Pharmacol. Ther.145: 43–57. doi:10.1016/j.pharmthera.2014.07.001. PMID25016186.
Connolly, KR; Thase, ME (2016). «Vortioxetine: a New Treatment for Major Depressive Disorder.». Expert Opinion on Pharmacotherapy17 (3): 421–31. doi:10.1517/14656566.2016.1133588. PMID26679430. «The authors suggest that vortioxetine is currently a good second-line antidepressant option and shows promise, pending additional long-term data, to become a first-line antidepressant option.».
Köhler, Stephan; Cierpinsky, Katharina; Kronenberg, Golo; Adli, Mazda (2016). «The serotonergic system in the neurobiology of depression: Relevance for novel antidepressants». Journal of Psychopharmacology30 (1): 13–22. doi:10.1177/0269881115609072. PMID26464458.
«Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder». Journal of Medicinal Chemistry54 (9): 3206–21. May 2011. doi:10.1021/jm101459g. PMID21486038.
Sanchez, C; Asin, KE; Artigas, F (1 January 2015). «Vortioxetine, a Novel Antidepressant with Multimodal Activity: Review of Preclinical and Clinical Data». Pharmacology & Therapeutics145: 43–57. doi:10.1016/j.pharmthera.2014.07.001. ISSN1879-016X. PMID25016186.
Sanchez, C; Asin, KE; Artigas, F (2015). «Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data». Pharmacol. Ther.145: 43–57. doi:10.1016/j.pharmthera.2014.07.001. PMID25016186.
Sanchez, C; Asin, KE; Artigas, F (1 January 2015). «Vortioxetine, a Novel Antidepressant with Multimodal Activity: Review of Preclinical and Clinical Data». Pharmacology & Therapeutics145: 43–57. doi:10.1016/j.pharmthera.2014.07.001. ISSN1879-016X. PMID25016186.